Insulin resistance increases the risk of incident type 2 diabetes mellitus in patients with non-alcoholic fatty liver disease. 2018

Yuya Seko, and Yoshio Sumida, and Saiyu Tanaka, and Kojiroh Mori, and Hiroyoshi Taketani, and Hiroshi Ishiba, and Tasuku Hara, and Akira Okajima, and Atsushi Umemura, and Taichiro Nishikawa, and Kanji Yamaguchi, and Michihisa Moriguchi, and Kazuyuki Kanemasa, and Kohichiroh Yasui, and Shunsuke Imai, and Keiji Shimada, and Yoshito Itoh
Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

OBJECTIVE Type 2 diabetes mellitus (T2DM) is a major complication of patients with non-alcoholic fatty liver disease (NAFLD). The aim of this retrospective study is to determine the risk factors for development of T2DM in patients with biopsy-proven NAFLD. METHODS One hundred and sixty two consecutive patients with biopsy-proven NAFLD who received a 75-g oral glucose tolerance test were enrolled as the total cohort. Among them, we analyzed 89 patients without T2DM diagnosed by oral glucose tolerance test to estimate the cumulative rate for development of T2DM as the follow-up cohort. RESULTS Of 162 patients, the glucose tolerance pattern were DM in 45 patients (27.8%), impaired glucose tolerance in 68 (42.0%), and normal glucose tolerance in 49 (30.2%). Patients with NAFL tended to be more likely to have normal glucose tolerance than those with non-alcoholic steatohepatitis (NASH). The serum levels of pre- and post-load insulin were significantly higher in the NASH group. Of 89 patients without T2DM, 13 patients newly developed T2DM during a follow-up period of 5.2 years. The cumulative rate of T2DM incidence was 8.8% at the end of the 5th year and 23.4% at the end of the 10th year. Multivariate analysis identified homeostasis model of assessment - insulin resistance (≥3.85, hazard ratio 40.1, P = 0.033) as an independent risk factor for development of T2DM. CONCLUSIONS Patients with NASH have an underlying potential of glucose intolerance. In NAFLD patients, insulin resistance is the most important risk factor for the incidence of T2DM. Appropriate therapy against insulin resistance could be needed for patients with NAFLD to prevent development of T2DM.

UI MeSH Term Description Entries

Related Publications

Yuya Seko, and Yoshio Sumida, and Saiyu Tanaka, and Kojiroh Mori, and Hiroyoshi Taketani, and Hiroshi Ishiba, and Tasuku Hara, and Akira Okajima, and Atsushi Umemura, and Taichiro Nishikawa, and Kanji Yamaguchi, and Michihisa Moriguchi, and Kazuyuki Kanemasa, and Kohichiroh Yasui, and Shunsuke Imai, and Keiji Shimada, and Yoshito Itoh
May 2024, Diabetes & metabolism journal,
Yuya Seko, and Yoshio Sumida, and Saiyu Tanaka, and Kojiroh Mori, and Hiroyoshi Taketani, and Hiroshi Ishiba, and Tasuku Hara, and Akira Okajima, and Atsushi Umemura, and Taichiro Nishikawa, and Kanji Yamaguchi, and Michihisa Moriguchi, and Kazuyuki Kanemasa, and Kohichiroh Yasui, and Shunsuke Imai, and Keiji Shimada, and Yoshito Itoh
November 2023, Diabetology & metabolic syndrome,
Yuya Seko, and Yoshio Sumida, and Saiyu Tanaka, and Kojiroh Mori, and Hiroyoshi Taketani, and Hiroshi Ishiba, and Tasuku Hara, and Akira Okajima, and Atsushi Umemura, and Taichiro Nishikawa, and Kanji Yamaguchi, and Michihisa Moriguchi, and Kazuyuki Kanemasa, and Kohichiroh Yasui, and Shunsuke Imai, and Keiji Shimada, and Yoshito Itoh
February 2016, Liver international : official journal of the International Association for the Study of the Liver,
Yuya Seko, and Yoshio Sumida, and Saiyu Tanaka, and Kojiroh Mori, and Hiroyoshi Taketani, and Hiroshi Ishiba, and Tasuku Hara, and Akira Okajima, and Atsushi Umemura, and Taichiro Nishikawa, and Kanji Yamaguchi, and Michihisa Moriguchi, and Kazuyuki Kanemasa, and Kohichiroh Yasui, and Shunsuke Imai, and Keiji Shimada, and Yoshito Itoh
January 2021, Frontiers in endocrinology,
Yuya Seko, and Yoshio Sumida, and Saiyu Tanaka, and Kojiroh Mori, and Hiroyoshi Taketani, and Hiroshi Ishiba, and Tasuku Hara, and Akira Okajima, and Atsushi Umemura, and Taichiro Nishikawa, and Kanji Yamaguchi, and Michihisa Moriguchi, and Kazuyuki Kanemasa, and Kohichiroh Yasui, and Shunsuke Imai, and Keiji Shimada, and Yoshito Itoh
July 2023, Pakistan journal of pharmaceutical sciences,
Yuya Seko, and Yoshio Sumida, and Saiyu Tanaka, and Kojiroh Mori, and Hiroyoshi Taketani, and Hiroshi Ishiba, and Tasuku Hara, and Akira Okajima, and Atsushi Umemura, and Taichiro Nishikawa, and Kanji Yamaguchi, and Michihisa Moriguchi, and Kazuyuki Kanemasa, and Kohichiroh Yasui, and Shunsuke Imai, and Keiji Shimada, and Yoshito Itoh
November 2009, Zhonghua nei ke za zhi,
Yuya Seko, and Yoshio Sumida, and Saiyu Tanaka, and Kojiroh Mori, and Hiroyoshi Taketani, and Hiroshi Ishiba, and Tasuku Hara, and Akira Okajima, and Atsushi Umemura, and Taichiro Nishikawa, and Kanji Yamaguchi, and Michihisa Moriguchi, and Kazuyuki Kanemasa, and Kohichiroh Yasui, and Shunsuke Imai, and Keiji Shimada, and Yoshito Itoh
January 2022, Journal of clinical and experimental hepatology,
Yuya Seko, and Yoshio Sumida, and Saiyu Tanaka, and Kojiroh Mori, and Hiroyoshi Taketani, and Hiroshi Ishiba, and Tasuku Hara, and Akira Okajima, and Atsushi Umemura, and Taichiro Nishikawa, and Kanji Yamaguchi, and Michihisa Moriguchi, and Kazuyuki Kanemasa, and Kohichiroh Yasui, and Shunsuke Imai, and Keiji Shimada, and Yoshito Itoh
April 2010, Zhonghua nei ke za zhi,
Yuya Seko, and Yoshio Sumida, and Saiyu Tanaka, and Kojiroh Mori, and Hiroyoshi Taketani, and Hiroshi Ishiba, and Tasuku Hara, and Akira Okajima, and Atsushi Umemura, and Taichiro Nishikawa, and Kanji Yamaguchi, and Michihisa Moriguchi, and Kazuyuki Kanemasa, and Kohichiroh Yasui, and Shunsuke Imai, and Keiji Shimada, and Yoshito Itoh
December 2021, Annals of medicine,
Yuya Seko, and Yoshio Sumida, and Saiyu Tanaka, and Kojiroh Mori, and Hiroyoshi Taketani, and Hiroshi Ishiba, and Tasuku Hara, and Akira Okajima, and Atsushi Umemura, and Taichiro Nishikawa, and Kanji Yamaguchi, and Michihisa Moriguchi, and Kazuyuki Kanemasa, and Kohichiroh Yasui, and Shunsuke Imai, and Keiji Shimada, and Yoshito Itoh
August 2022, Journal of gastroenterology and hepatology,
Copied contents to your clipboard!